We are dedicated to developing and commercializing innovative vaccines that modulate the immune system to prevent disease. About Dynavax Technologies Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. Dynavax develops, and commercializes novel vaccines. We are committed to a rigorous approach to drug development in the field of TLR biology so that we may help physicians and patients address unmet needs. Our vision and work ethic are guided by the collective ideals underpinning our corporate values, and these form the basis of our company culture. Management Team Our management team is comprised of industry veterans that have extensive expertise in drug development and commercialization. With experience spanning successful biopharmaceutical companies to pertinent government organizations, they bring a rich knowledge-base to lead a growing fast-paced company. Ryan Spencer CHIEF EXECUTIVE OFFICER David Novack PRESIDENT AND CHIEF OPERATING OFFICER Robert Janssen CHIEF MEDICAL OFFICER Kelly MacDonald CHIEF FINANCIAL OFFICER Donn Casale SENIOR VICE PRESIDENT, COMMERCIAL Jeff Coon SENIOR VICE PRESIDENT HUMAN RESOURCES AND ADMINISTRATION Todd Lopeman SENIOR VICE PRESIDENT, TECHNICAL OPERATIONS John L. Slebir SENIOR VICE PRESIDENT, GENERAL COUNSEL Dong Yu SENIOR VICE PRESIDENT, VACCINE RESEARCH Eric Frings VICE PRESIDENT, SITE HEAD AND MANAGING DIRECTOR Riccardo Manetti VICE PRESIDENT, BUSINESS DEVELOPMENT Patricia Novy VICE PRESIDENT, MEDICAL AFFAIRS Meg Smith VICE PRESIDENT, SALES AND OPERATIONS Board of Directors Our Board of Directors is a well-established group with broad leadership backgrounds. Their current and previous roles as biotech executives, physicians, researchers, and investors provides us with multifaceted expertise to help us reach our shared vision for helping patients. Scott D. Myers, MBA CHAIRMAN OF THE BOARD Francis R. Cano, Ph.D. Julie Eastland Andrew Hack, M.D., Ph.D. Daniel L. Kisner, M.D. Brent MacGregor Peter Paradiso, Ph.D. Peggy V. Phillips Natale (“Nat”) Ricciardi Ryan Spencer Dynavax Europe Dynavax GmbH (Dynavax Europe), is the European affiliate of Dynavax Technologies Corporation. For more than 25 years, we have been dedicated to the development and manufacturing of vaccines and biopharmaceuticals. LEARN MORE CAREERS CONTACT TERMS OF USE PRIVACY NOTICE © 2021 Dynavax Technologies. All rights reserved. Website Design: Hane Chow, Inc. US-19-00-00200

Skip to main navigation Stock Information Stock Quote NASDAQ: DVAX $16.39 Nov 24, 2021 4:00 PM EST Change+0.59 (+3.73%) Volume1,295,894 Today's Open$15.94 Previous Close$15.80 Today's High$16.49 Today's Low$15.60 52 Week High$21.39 52 Week Low$4.06 Stock Chart Data Provided by Refinitiv. Minimum 15 minutes delayed. Email Alerts RSS Print Share Search ABOUT PRODUCT SCIENCE PORTFOLIO ONGOING STUDIES CAREERS CONTACT © 2021 Dynavax Technologies. All rights reserved. Website Design: Hane Chow, Inc.